Cell-based immunotherapies in gynecologic cancers
Purpose of review
This review provides an update on recent developments in cell-based immunotherapy in gynecologic cancers.
Recent findings
Chimeric antigen receptor (CAR) technology has made significant progress allowing now for not only expressing CARs on T-cells, but also on other immune effector cells, such as natural killer cells and macrophages. Cell-based vaccines have started to show promising results in clinical trials.
Summary
Cell-based immunotherapies in gynecologic cancers continue to evolve with promising clinical efficacy in select patients.
Source: Current Opinion in Obstetrics and Gynecology - Category: OBGYN Tags: GYNECOLOGIC CANCER: Edited by Gottfried E. Konecny Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Immunotherapy | OBGYN | Vaccines